MedTrace Logo

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2014-05-02

No results posted yet for this study

Summary

This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins potentially associated with parkinsonian syndrome. Participants will have brain imaging to assess dopamine transporter density. The imaging data coupled with family history and environmental exposure data may provide important information about potential risk factors for parkinsonian syndrome.

Conditions

  • Parkinsonian Syndrome

Interventions

DRUG

[123I]ß CIT and SPECT imaging

To assess \[123I\]ß CIT and SPECT imaging

Sponsors & Collaborators

  • Indiana University

    collaborator OTHER

  • Albany Medical College

    collaborator OTHER

  • Institute for Neurodegenerative Disorders

    lead OTHER

Principal Investigators

  • Kenneth L. Marek, MD · President and Senior Scientist

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00117819 on ClinicalTrials.gov